Biologyarticle2026-09-27

Lithium chloride in vitro treatment shows potential to rescue the neuronal phenotype caused by WDFY3 haploinsufficiency

Open access0 citations

Abstract

We provide a comprehensive phenotypic characterization of loss-of-function (LoF) variants in WDFY3 based on the largest cohort reported to date (n = 32). Our findings define a monogenic disorder marked by neuropsychiatric features (including autism and ADHD), mild to moderate neurodevelopmental delay, and variable brain growth - most commonly macrocephaly and in one case reduced head circumference. To investigate the effect of WDFY3 LoF we performed knockdown (KD) in the human neuroblastoma cell line SH-SY5Y and used a Wdfy3-haploinsufficient mouse model. WDFY3 KD impaired clearance of protein aggregates and decreased protein levels of the ubiquitin-binding protein p62. Transcriptomic analyses identified dysregulation in gene networks that are primarily involved in nervous system development, neuron projection, MAPK/ERK1/2, and WNT/β-catenin signaling. This was confirmed at protein level. Neuronal cell proliferation was increased, as evidenced by elevated cell counts and proliferation markers Ki-67 and PCNA. Conversely, neuronal cell differentiation was impaired, as indicated by reduced neurite outgrowth. We show that β-catenin is downregulated, while GSK3B is upregulated. LiCl activates WNT/β-catenin signaling by inhibiting GSK3B. We thus tested LiCl treatment, which significantly increased WDFY3 expression. Moreover, in vitro treatment improved the neurite branching capacity of Wdfy3-haploinsufficient neurons above the level of the wild type, although this specific effect appeared independent of WNT/β-catenin signaling. In sum, we expand on the phenotype related to WDFY3 LoF and provide insights into the pathophysiology using in vitro human and murine neuronal models. Our findings suggest that LiCl may serve as a potential therapeutic strategy for patients with WDFY3 LoF variants.

// Source

View paper (DOI)Open access versionOpenAlexMolecular PsychiatryPublished 2026-09-27

Authors: Moritz J. Paha, Arshi Mustafa, Lyvin Tat, Sandy Richter, Linnaeus Bundalian, Sworadip CHOWDHURY, Akhil Velluva, Robin-Tobias Jauss, Knut Krohn, Kathleen Schön, Max Holzer, Anna Sophia Kirstein, Meena Balasubramanian, María Juliana Ballesta‐Martínez, Lynne M. Bird, Kirsty Bradshaw, Ange-Line Bruel, Alfredo Brusco, Yanmin Chen, Aurore Garde, Silvia Guarducci, Yoel Gofin, Rachel E. Harrison, Alexis R. Heidlebaugh, Anna Hurst, Julián A. Martínez-Agosto, Jessica L. Mester, Alistair T. Pagnamenta, Marilena Pantaleo, Andrea Paras, Angela Peron, Tiziana Pisano, Ahna M. Rabani, Marcello Scala, Elena Shukarova-Angelovska, Yang Sui, Slavica Trajkova, Sheila Umayam, Tianyun Wang, Rami Abou Jamra, Johannes R. Lemke, Wieland Kiess, Konstantinos S. Zarbalis, Antje Garten, Diana Le Duc

Institutions: University of California, Los Angeles, University of Washington, Northwestern University, Rady Children's Hospital-San Diego, University of California San Diego, Peking University, University of Sheffield, University of Exeter, University of Alabama at Birmingham, Leipzig University, Inserm, Instituto de Salud Carlos III, University Hospital Carl Gustav Carus, University of Florence, Hospital Universitario Virgen de la Arrixaca, Tel Aviv University, University of Turin, University Hospital Leipzig, University of California, Davis, Meyer Children's Hospital, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, University of Genoa, Technische Universität Dresden, Nottingham City Hospital, Istituto Giannina Gaslini, Lurie Children's Hospital, Centre for Human Genetics, Université de Bourgogne, CHU Dijon Bourgogne, University Clinic of Traumatology, Sheffield Children's NHS Foundation Trust, Meir Medical Center, Kennedy Krieger Institute, Centre de recherche Translationnelle en Médecine moléculaire